References
- Caro J, Möller J. Advantage and disadvantages of discrete-event simulation for health economic analyses. Expert Rev Pharmacoecon Outcomes Res. 2016;16(3):327–329.
- Davis S, Stevenson M, Tappenden P, et al. NICE DSU technical support document 15: cost-effectiveness modelling using patient-level simulation. 2014. Available from: http://www.nicedsu.org.uk, 2016 Oct 5th
- Karnon J, Afzali H. When to use Discrete Event Simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES. PharmacoEconomics. 2014;32:547–558.
- Stanfield L, Commons T, Scuffham P. Markov modeling and discrete event simulation in health care: a systematic comparison. Int J Technol Assess Health Care. 2014;30(2):165–172.
- Afzali H, Karnon J, Gray J. A critical review of model-based economic studies of depression. Modelling techniques, model structure and data sources. PharmacoEconomics. 2012;30(6):461–482.
- Scholz S, Mittendorf T. Modeling rheumatoid arthritis using different techniques – a review of model construction and results. Health Econ Rev. 2014;4(18):1–16.
- Henriksson M, Jindal R, Sternhufvud C, et al. A systematic review of cost-effectiveness models in type 1 diabetes mellitus. PharmacoEconomics. 2016;34(6):569–585.
- Ramaekers B, Joore M, Grutters J. How should we deal with patient heterogeneity in economic evaluation: a systematic review of national pharmacoeconomic guidelines. Value Health. 2013;16:855–862.
- Soares M, Castro L. Continous time simulation and discretized models for cost-effectiveness analysis. PharmacoEconomics. 2012;30(12):1101–1117.
- The National Institute for Health and Care Excellence (NICE). NICE Process [PMG19]. Guide to the processes of technology appraisal. 2014. Available from: https://www.nice.org.uk/process/pmg19/chapter/the-appraisal-process, 2016 Oct 4th
- The National Institute for Health and Care Excellence (NICE). Technology appraisal guidance [TA387]. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. Available from: https://www.nice.org.uk/guidance/ta387/chapter/4-Committee-discussion#cost-effectiveness-2, 2016 Oct 5th
- Caro J. Discretely Integrated Condition Event (DICE) simulation for pharmacoeconomics. Pharmacoeconomics. 2016;34(7):665–672.
- Toumi M, Beck E, Sherman S, et al. Discretely Integrated Condition Event Simulation for Pharmacoeconomics. Pharmacoeconomics. 2016. DOI:10.1007/s40273-016-0449-1
- Evidera. DICE: A unifying modeling approach expressly designed to meet the needs of health economic analysis. DICE factsheet. 2016. Available from: http://www.evidera.com/wp-content/uploads/DICE-factsheet_july2016.pdf, 2016 Oct 4th
- Caro J. Response to letter to the editor regarding discretely integrated condition event simulation for pharmacoeconomics. Pharmacoeconomics. 2016. DOI:10.1007/s40273-016-0450-8.
- DICE. a unifying modeling approach expressly designed to meet the needs of health economic analysis. Bethesda: Evidera; 2015 [cited 2016 Oct 4th]. Available from: http://www.evidera.com/dice/
- Caro J Rolling the DICE: discretely integrated condition event simulation for health economic analyses. White Paper – The Evidence Forum May 2016. Available from: http://www.evidera.com/wp-content/uploads/11-Rolling-the-DICE-2016.pdf, cited 2016 Oct 4th